8-K: Avanos Medical Announces Executive Departures and Appointments

Avanos Medical reports the departure of Interim CEO Michael Greiner and Interim CFO Warren Machan, along with the appointment of Jason Pickett as Interim CFO and Treasurer.

Summary

• Avanos Medical, Inc. announced the departure of Michael C. Greiner, who served as Interim Chief Executive Officer, effective April 18, 2025.
• Greiner's departure is due to the company not offering him a position comparable to his previous role.
• He will receive a severance payment of $2,100,000, a prorated bonus for 2025, six months of COBRA premiums, and $50,000 in consulting fees for a one-month engagement.
• All of Greiner's special equity awards will vest immediately, while other unvested equity awards will terminate.
• Warren J. Machan's consulting agreement was amended, and he no longer serves as Interim Chief Financial Officer as of April 14, 2025.
• Machan will continue as a consultant until April 30, 2025, receiving $60,000 per month but waiving his right to a $45,000 bonus.
• Jason M. Pickett has been appointed as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.
• Pickett has been with the company since 2014 and previously served as Vice President, Tax and Treasurer.
• His compensation details will be disclosed in an amendment to this report.

Sentiment

Score: 6

Explanation: The announcement is neutral. While there are executive departures, the company has a plan in place and has appointed an interim CFO. The financial impact is limited to severance and consulting fees.

Positives

• The company has a Severance Pay Plan in place to provide benefits to departing executives.
• Jason Pickett's appointment provides continuity in the finance department, given his long tenure with the company.
• Greiner has agreed to remain with the Company in a consulting capacity until May 16, 2025.

Negatives

• The departure of both the Interim CEO and Interim CFO within a short period could create uncertainty.
• The company had to pay a $2,100,000 severance to the departing Interim CEO.
• The company will pay Mr. Machan a fixed rate of $60,000 per month through April 30, 2025.

Risks

• The transition to a new Interim CFO could pose challenges to financial reporting and compliance.
• The company has not yet determined Mr. Pickett's compensation, and the Company has not yet entered into any contract or arrangement with Mr. Pickett in connection with his role as Interim Chief Financial Officer and Treasurer.
• The company will file an amendment to this Current Report on Form 8-K containing such information within four business days after the information is determined or becomes available.

Future Outlook

The company will file an amendment to this Current Report on Form 8-K containing such information within four business days after the information is determined or becomes available regarding Mr. Pickett's compensation.

Management Comments

• Michael C. Greiner announced that he will leave Avanos Medical, Inc. to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company's Interim Chief Executive Officer.

Industry Context

Executive transitions are common in the medical device industry, often driven by strategic shifts or performance considerations. Companies often use interim roles to bridge gaps during leadership searches.

Comparison to Industry Standards

• Severance packages for executives typically include a combination of base salary, bonus, equity, and benefits continuation, aligning with industry norms.
• Consulting agreements are frequently used to retain expertise during transitions, as seen with Warren Machan's continued role.
• Companies like Medtronic and Johnson & Johnson also have well-defined severance plans for executives.

Management Changes

Stakeholder Impact

• Shareholders may react to the executive changes, but the company's established plans should mitigate concerns.
• Employees may experience some uncertainty during the transition, but the company's actions appear to be orderly.
• Customers and suppliers are unlikely to be significantly affected by these changes.

Next Steps

• Avanos Medical will file an amendment to this report with details of Mr. Pickett's compensation.
• The company will continue to operate under the leadership of the new Interim CFO and CEO.

Key Dates

Keywords

executive departure, chief financial officer, chief executive officer, severance, appointment, Avanos Medical